Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables Refunds
Ratios

Keros Therapeutics (KROS) Accumulated Depreciation & Amortization (2019 - 2025)

Keros Therapeutics (KROS) has disclosed Accumulated Depreciation & Amortization for 6 consecutive years, with $2.9 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Accumulated Depreciation & Amortization rose 71.45% year-over-year to $2.9 million, compared with a TTM value of $2.9 million through Dec 2024, up 71.45%, and an annual FY2024 reading of $2.9 million, up 71.45% over the prior year.
  • Accumulated Depreciation & Amortization was $2.9 million for Q4 2024 at Keros Therapeutics, up from $1.7 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $2.9 million in Q4 2024 and bottomed at $721000.0 in Q4 2020.
  • Average Accumulated Depreciation & Amortization over 5 years is $1.5 million, with a median of $1.2 million recorded in 2022.
  • The sharpest move saw Accumulated Depreciation & Amortization increased 17.34% in 2021, then skyrocketed 71.45% in 2024.
  • Year by year, Accumulated Depreciation & Amortization stood at $721000.0 in 2020, then increased by 17.34% to $846000.0 in 2021, then surged by 37.47% to $1.2 million in 2022, then soared by 47.89% to $1.7 million in 2023, then surged by 71.45% to $2.9 million in 2024.
  • Business Quant data shows Accumulated Depreciation & Amortization for KROS at $2.9 million in Q4 2024, $1.7 million in Q4 2023, and $1.2 million in Q4 2022.